Insights on Clinical Trials
-
Rescuing A Global Program For NDA Success
8/12/2025
Explore the collaboration that enabled FDA approval of a novel chronic-condition therapy, rescued a high-risk program, and demonstrated a unified “one-team” approach by reworking the sponsor's SAP.
-
AI-Enhanced Clinical Project Management For Cell And Gene Therapy Clinical Trials
8/12/2025
Consultant Jessica Cordes explores two of the most critical uses of AI for cell and gene therapy clinical trials: real-time patient journey coordination and predictive enrollment.
-
Best Practices For Regulatory Excellence In Clinical Research
8/7/2025
Observe how GCLP can integrate ethical and technical standards to ensure reliable, compliant clinical trial data and optimize laboratory operations across sponsors, CROs, and partners.
-
ASCO 2025: Key Takeaways From The American Society Of Clinical Oncology Annual Meeting
7/31/2025
Cell and gene therapy for cancer continues to advance. New data show promise, alongside discussions on safety and scalability.
-
Comply With The New NIH Transparency Rules For r/sNA Molecule Research
7/30/2025
Review new transparency requirements for NIH-funded institutions engaged in research involving r/sNA molecules and regulations for Institutional Biosafety Committees (IBCs).
-
Optimizing Commercial Distribution As You Prepare To Launch Your CGT
7/29/2025
An effective commercial distribution strategy is crucial for new cell and gene therapies, helping manufacturers navigate challenges and ensure patient access.
-
Strategies For Optimizing iPSC Cryopreservation, Storage, And Post-Thaw Quality
7/29/2025
Developing iPSC therapies demands meticulous cryopreservation, smart automation, and risk-based post-thaw quality control to bridge lab development with cGMP manufacturing. The sensitivity of iPSCs requires tailored protocols and a deep understanding of cell behavior under scaled conditions, ensuring consistent, viable products.
-
Guiding Principles For Process Development And IND Readiness
7/25/2025
Observe how a milestone-driven risk management strategy streamlines cell therapy development, reduces uncertainty, and aligns early decisions with long-term commercialization and regulatory success.
-
GLP‑1 Clinical Trial Eye Safety: Semaglutide Eye Risks
7/24/2025
While GLP-1 receptor agonists offer significant health benefits, proactive eye care and vigilance are essential to mitigate the risk of irreversible ocular conditions.
-
Clinical Trial Support: Point Of Need vs. Traditional Solutions
7/24/2025
Examine the limitations of traditional, fixed-location ophthalmic trial sites and how a mobile assessment model can significantly improve patient retention while ensuring high-quality data collection.